Moving Forward in Alzheimer’s Disease: New Management Paradigms for Patients and Healthcare Systems

Target Audience
The educational design of this activity addresses the needs of neurology, psychiatry, and gerontology specialists involved in the treatment of patients with Alzheimer’s disease (AD).

Statement of Need/Program Overview
Alzheimer’s disease (AD) is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. The current understanding of the complex pathophysiology of AD has led to the development of therapies that target amyloid β, tau, and neuroinflammation. Despite its prevalence and significant associated medical, psychosocial, and economic burdens, AD often remains undiagnosed and untreated. As new pathophysiology-linked biomarkers become available and incorporated into practice, diagnosis will improve, thus improving management strategies. However, newer management strategies may result in changes to infrastructure, which will impact each clinician’s practice. In this CME SnapShot series, Dr. Turner and Dr. Cohen will examine AD pathophysiology, optimal strategies to screen patients with suspected mild cognitive impairment (MCI) or AD, the differential diagnoses of MCI and AD, current evidence and regulatory status for newer targeted therapies, ongoing health care disparities in the management of these patients, and potential changes to health care systems as new treatment options become available.

Module 1: Pathophysiology of Alzheimer's Disease
Module 2: Evaluation and Diagnosis of MCI and AD
Module 3: Management of AD
Module 4: Barriers to Optimizing Alzheimer's Disease Management

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term Offering
This activity was released on February 17, 2022 and is valid for 1 year. Requests for credit must be made no later than February 17, 2023.

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.

Disclosures of Conflicts of Interest
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sharon Cohen, MD, FRCPC Nothing to disclose

R. Scott Turner, PhD, MD Consulting Fee: Jupiter Pharmaceutical Limited; Research Support to Georgetown University: Biogen MA, Inc, Eli Lilly and Company, Genentech, Inc., Novartis International AG, Eisai Co., Ltd., Vaccinex Inc.

The following planners and managers have no relevant financial relationships with ineligible companies:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Stacey JP Ullman, MHS, Jim Kappler, PhD

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirement

PC
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)

Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome

For HTML Client " Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

MAC
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14

Mozilla Firefox, Apple Safari, Google Chrome

For HTML Client " Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)